SCHEMBL4469992

SCHEMBL4469992

CC(C)Cn1c(=O)n(C)c(=O)c2c1ncn2CCNCc1ccccc1O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 1/20 0.59
PDE1B Q01064 1/20 0.59
PDE1C Q14123 1/20 0.59
SMN1; SMN2 Q16637 3/20 0.48
ALDH1A1 P00352 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PDE4A P27815 4/20 0.45
PDE4B Q07343 4/20 0.45
PDE4C Q08493 4/20 0.45
PDE4D Q08499 4/20 0.45
ADORA2A P29274 2/20 0.45
ADORA2B P29275 1/20 0.45
LMNA P02545 1/20 0.43
CASP1 P29466 1/20 0.43
CNOT7 Q9UIV1 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480581 0.87 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1ADORA2BLMNACASP1
SCHEMBL4472695 0.86 PDE1A (0.56) PDE1APDE1BPDE1CSMN1; SMN2ALDH1A1
SCHEMBL4460628 0.85 PDE1A (0.48) PDE1APDE1BPDE1CSMN1; SMN2ALDH1A1
SCHEMBL4464164 0.77 PDE1A (0.46) PDE1APDE1BPDE1CALDH1A1PDE4A
SCHEMBL11033822 0.76 PDE1A (0.73) PDE1APDE1BPDE1CSMN1; SMN2ALDH1A1
SCHEMBL4483780 0.76 PDE4A (0.46) PDE1APDE1BPDE1CPDE4APDE4B
SCHEMBL11004837 0.74 PDE4A (0.73) PDE1APDE1BPDE1CSMN1; SMN2PDE4A
SCHEMBL4471527 0.74 PDE1A (0.67) PDE1APDE1BPDE1CSMN1; SMN2PDE4A
SCHEMBL7089727 0.74 ADORA2B (0.68) PDE1APDE1BPDE1CSMN1; SMN2PDE4A
SCHEMBL11012550 0.72 PDE1A (0.64) PDE1APDE1BPDE1CSMN1; SMN2PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550468-B2 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase CHEN ING-JUN 2009-06-23 US disclosed
US-20050209242-A1 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase CHEN ING-JUN 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209242-A1 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase PDE3A, PDE5A, PDE3B PDE1A 22/4885PDE1B 24/4885PDE1C 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.